Drs. Weber, Luke, and Gangadhar discuss the latest updates to existing immunotherapies and examine where the future may lie.
This activity is intended for hematologists, oncologists, dermatologists, and pathologists.
The goal of this activity is to review the latest advances in immunotherapy for melanoma.
Approximate Time to Complete: 35 minutes
Course Available Beginning: Aug. 31, 2016
Developed through a partnership between SITC and Medscape.
Upon completion of this activity, participants will be able to:
- Examine emerging clinical trial data on the use of immune-oncologic agents in the management of melanoma
- Evaluate the implications of recent clinical data on treatment strategies for patients with melanoma in the community oncology setting